CY1124554T1 - Μεθοδοι και συνθεσεις για διεγερση του εντερικου εντεροενδοκρινους συστηματος για θεραπεια ασθενειων ή καταστασεων που σχετιζονται προς αυτο - Google Patents
Μεθοδοι και συνθεσεις για διεγερση του εντερικου εντεροενδοκρινους συστηματος για θεραπεια ασθενειων ή καταστασεων που σχετιζονται προς αυτοInfo
- Publication number
- CY1124554T1 CY1124554T1 CY20211100573T CY211100573T CY1124554T1 CY 1124554 T1 CY1124554 T1 CY 1124554T1 CY 20211100573 T CY20211100573 T CY 20211100573T CY 211100573 T CY211100573 T CY 211100573T CY 1124554 T1 CY1124554 T1 CY 1124554T1
- Authority
- CY
- Cyprus
- Prior art keywords
- stimulating
- methods
- diseases
- compositions
- treatment
- Prior art date
Links
- 230000004936 stimulating effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 210000000750 endocrine system Anatomy 0.000 title 1
- 230000000968 intestinal effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 abstract 1
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 abstract 1
- 241000251778 Squalus acanthias Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000000105 enteric nervous system Anatomy 0.000 abstract 1
- 229950001248 squalamine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462015657P | 2014-06-23 | 2014-06-23 | |
| US14/329,627 US10040817B2 (en) | 2013-10-03 | 2014-07-11 | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
| PCT/US2015/036935 WO2015200195A1 (en) | 2014-06-23 | 2015-06-22 | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124554T1 true CY1124554T1 (el) | 2022-07-22 |
Family
ID=54869043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100573T CY1124554T1 (el) | 2014-06-23 | 2021-06-28 | Μεθοδοι και συνθεσεις για διεγερση του εντερικου εντεροενδοκρινους συστηματος για θεραπεια ασθενειων ή καταστασεων που σχετιζονται προς αυτο |
Country Status (19)
| Country | Link |
|---|---|
| US (10) | US10040817B2 (enExample) |
| EP (1) | EP3157531B1 (enExample) |
| JP (2) | JP6692300B2 (enExample) |
| CN (2) | CN113559108A (enExample) |
| BR (1) | BR112016029917A2 (enExample) |
| CA (1) | CA2951720C (enExample) |
| CY (1) | CY1124554T1 (enExample) |
| DK (1) | DK3157531T3 (enExample) |
| ES (1) | ES2878077T3 (enExample) |
| HR (1) | HRP20211005T1 (enExample) |
| HU (1) | HUE054828T2 (enExample) |
| LT (1) | LT3157531T (enExample) |
| MX (2) | MX382442B (enExample) |
| PL (1) | PL3157531T3 (enExample) |
| PT (1) | PT3157531T (enExample) |
| RS (1) | RS62064B1 (enExample) |
| SI (1) | SI3157531T1 (enExample) |
| SM (1) | SMT202100373T1 (enExample) |
| WO (1) | WO2015200195A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10040817B2 (en) * | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
| US20160058730A1 (en) * | 2014-08-29 | 2016-03-03 | Cadila Healthcare Limited | Pharmaceutical compositions of teriflunomide |
| WO2018222665A1 (en) * | 2017-05-31 | 2018-12-06 | Enterin Laboratories, Inc. | Methods and compositions for preventing or treating inflammatory diseases |
| EP3678671A4 (en) * | 2017-09-08 | 2022-12-07 | Enterin, Inc. | METHODS OF TREATMENT OF SLEEPING DISEASES, SLEEP DISORDERS AND RELATED SYMPTOMS USING AMINOSTEROL COMPOSITIONS |
| MA50536A (fr) * | 2017-10-30 | 2020-09-09 | Enterin Inc | Nouvelles formes solides de squalamine et procédés pour les produire |
| KR20200146038A (ko) * | 2018-03-27 | 2020-12-31 | 엔테린, 인코포레이티드 | 환각 및 이와 관련된 상태를 치료하는 방법 및 조성물 |
| JP2021527090A (ja) * | 2018-06-13 | 2021-10-11 | エンターイン、 インコーポレイテッドＥｎｔｅｒｉｎ， Ｉｎｃ． | 老化関連神経変性の進行および／または発症を治療および／または予防するための方法および組成物 |
| US11464789B2 (en) | 2018-08-03 | 2022-10-11 | Enterin, Inc. | Aminosterol compositions and methods of using the same for treating schizophrenia |
| WO2020028810A1 (en) * | 2018-08-03 | 2020-02-06 | Enterin Laboratories | Compositions and methods for treating brain-gut disorders |
| WO2020028791A1 (en) * | 2018-08-03 | 2020-02-06 | Enterin Laboratories | Low dosage intranasal aminosterol dosage forms and methods of using the same |
| US20210315907A1 (en) * | 2018-08-03 | 2021-10-14 | Enterin, Inc, | Compositions and methods for treating brain-gut disorders |
| US20230125585A1 (en) * | 2019-08-02 | 2023-04-27 | Enterin, Inc. | Dosing protocols and regimens for aminosterol treatment |
| CN115551871A (zh) * | 2020-03-19 | 2022-12-30 | 因特尔公司 | 角鲨胺的晶型 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5192756A (en) | 1992-03-18 | 1993-03-09 | The Children's Hospital Of Pennsylvania | Aminosterol antibiotic |
| US5352682A (en) | 1993-03-08 | 1994-10-04 | Digestive Care Inc. | Compositions containing salts of bile acid-aminosalicylate conjugates |
| CA2157594A1 (en) | 1993-03-10 | 1994-09-15 | Leah L. Frye | Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants |
| US5840740A (en) | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds and a method of treating infection using the aminosterol compounds |
| US5856535A (en) | 1994-08-18 | 1999-01-05 | Magainin Pharmaceuticals, Inc. | Aminosterol ester compounds |
| AU3512595A (en) | 1994-09-13 | 1996-03-29 | Magainin Pharmaceuticals, Inc. | Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds |
| US5834453A (en) | 1995-05-30 | 1998-11-10 | Lehigh University | Methods for the manufacture and use of antimicrobial sterol conjugates |
| US5795885A (en) | 1995-06-07 | 1998-08-18 | Magainin Pharmaceuticals Inc. | Method of inhibiting profileration of cells by administering an aminosterol compound |
| AU723663C (en) * | 1995-06-07 | 2001-11-01 | Magainin Pharmaceuticals, Inc. | Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds |
| US5994336A (en) | 1995-06-07 | 1999-11-30 | Magainin Pharmaceuticals Inc. | Method of inhibiting proliferation of cells by administering an aminosterol compound |
| US6143738A (en) | 1995-06-07 | 2000-11-07 | Magainin Pharmaceuticals, Inc. | Therapeutic uses for an aminosterol compound |
| US5874597A (en) | 1995-06-07 | 1999-02-23 | Magainin Pharmaceuticals, Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| US5847172A (en) | 1995-06-07 | 1998-12-08 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| US5763430A (en) | 1995-06-07 | 1998-06-09 | Magainin Pharmaceuticals Inc. | Method of treating a viral infection by administering a steroid compound |
| US5840936A (en) | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE) |
| US5792635A (en) | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| US5744453A (en) | 1996-01-05 | 1998-04-28 | Mintz; Clifford S. | Polyamine conjugates for treatment of infection |
| US6596712B2 (en) | 1996-04-26 | 2003-07-22 | Genaera Corporation | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
| PT910382E (pt) | 1996-04-26 | 2003-10-31 | Genaera Corp | Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores |
| US7410959B1 (en) * | 2000-07-13 | 2008-08-12 | Genaera Corporation | Therapeutic uses for aminosterol compounds |
| JP2002515035A (ja) | 1996-05-17 | 2002-05-21 | ジェネーラ・コーポレーション | アミノステロール化合物の治療学的使用 |
| WO1998019682A1 (en) | 1996-11-01 | 1998-05-14 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and uses therefor |
| CA2339174C (en) | 1998-08-12 | 2009-01-06 | Magainin Pharmaceuticals, Inc. | Aminosterol compounds and uses thereof |
| US6288089B1 (en) * | 1998-12-21 | 2001-09-11 | Michael Zawada | Use of kinase inhibitors for treating neurodegenerative diseases |
| AU2002230398A1 (en) | 2000-10-06 | 2002-04-29 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
| WO2002044324A2 (en) * | 2000-10-06 | 2002-06-06 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
| ES2716404T3 (es) * | 2002-01-28 | 2019-06-12 | Kyowa Hakko Kogyo Kk | Antagonistas de receptores A2A para su uso en el tratamiento de trastornos del movimiento |
| WO2004034963A2 (en) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| US7981876B2 (en) | 2005-04-25 | 2011-07-19 | Ohr Pharmaceuticals, Inc. | Polymorphic and amorphous salt forms of squalamine dilactate |
| CA2985271A1 (en) | 2007-09-06 | 2009-03-12 | Ohr Pharmaceutical, Inc. | A method for treating diabetes |
| US8247435B2 (en) * | 2009-02-19 | 2012-08-21 | Thornthwaite Jerry T | Formulations for treating human and animal diseases |
| WO2011056650A2 (en) | 2009-10-27 | 2011-05-12 | Michael Zasloff | Methods and compositions for treating and preventing viral infections |
| WO2011066260A2 (en) | 2009-11-25 | 2011-06-03 | Michael Zasloff | Formulations comprising aminosterols |
| KR20150003798A (ko) | 2012-04-20 | 2015-01-09 | 오에이치알 파마서티컬, 인코포레이티드 | Ptp1b 연관 질병의 치료용 아미노스테로이드 |
| CN102813659A (zh) * | 2012-08-21 | 2012-12-12 | 贵阳中医学院 | 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途 |
| EP2934543B1 (en) | 2012-12-20 | 2018-10-31 | Mount Desert Island Biological Laboratory | Stimulation and enhancement of regeneration of tissues |
| US10040817B2 (en) | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
-
2014
- 2014-07-11 US US14/329,627 patent/US10040817B2/en active Active
-
2015
- 2015-06-22 EP EP15811714.3A patent/EP3157531B1/en active Active
- 2015-06-22 LT LTEP15811714.3T patent/LT3157531T/lt unknown
- 2015-06-22 BR BR112016029917A patent/BR112016029917A2/pt not_active Application Discontinuation
- 2015-06-22 HR HRP20211005TT patent/HRP20211005T1/hr unknown
- 2015-06-22 DK DK15811714.3T patent/DK3157531T3/da active
- 2015-06-22 CN CN202110489234.7A patent/CN113559108A/zh active Pending
- 2015-06-22 MX MX2016017368A patent/MX382442B/es unknown
- 2015-06-22 WO PCT/US2015/036935 patent/WO2015200195A1/en not_active Ceased
- 2015-06-22 PT PT158117143T patent/PT3157531T/pt unknown
- 2015-06-22 PL PL15811714T patent/PL3157531T3/pl unknown
- 2015-06-22 SM SM20210373T patent/SMT202100373T1/it unknown
- 2015-06-22 JP JP2016574402A patent/JP6692300B2/ja active Active
- 2015-06-22 RS RS20210819A patent/RS62064B1/sr unknown
- 2015-06-22 CA CA2951720A patent/CA2951720C/en active Active
- 2015-06-22 SI SI201531637T patent/SI3157531T1/sl unknown
- 2015-06-22 HU HUE15811714A patent/HUE054828T2/hu unknown
- 2015-06-22 ES ES15811714T patent/ES2878077T3/es active Active
- 2015-06-22 CN CN201580033333.7A patent/CN106535902B/zh active Active
-
2016
- 2016-12-20 MX MX2021005489A patent/MX2021005489A/es unknown
-
2017
- 2017-05-24 US US15/604,527 patent/US10208080B2/en active Active
- 2017-05-24 US US15/604,489 patent/US10208079B2/en active Active
- 2017-05-24 US US15/604,452 patent/US10196420B2/en active Active
-
2018
- 2018-07-13 US US16/035,537 patent/US10633413B2/en active Active
- 2018-07-18 US US16/039,294 patent/US11440936B2/en active Active
- 2018-12-13 US US16/219,879 patent/US20190185513A1/en not_active Abandoned
- 2018-12-13 US US16/219,848 patent/US10975116B2/en active Active
- 2018-12-14 US US16/220,860 patent/US20190194244A1/en not_active Abandoned
-
2020
- 2020-01-21 JP JP2020007206A patent/JP7010979B2/ja active Active
-
2021
- 2021-06-28 CY CY20211100573T patent/CY1124554T1/el unknown
-
2022
- 2022-04-01 US US17/711,891 patent/US20220220148A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021005489A (es) | Metodos y composiciones para la estimulacion del sistema enteroendocrino intestinal para el tratamiento de enfermedades o condiciones relacionadas con el mismo. | |
| IL290980A (en) | Rna for the treatment of autoimmune diseases | |
| EP3618829A4 (en) | QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER ASSOCIATED DISORDERS | |
| EP4378536A3 (en) | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | |
| EP3347464A4 (en) | DNASE-H ACTIVITY OF NEISSERIA MENINGITIDIS CAS9 | |
| EP3259017A4 (en) | Nerve stimulation for treatment of diseases and disorders | |
| EA201791095A1 (ru) | Способ лечения рака | |
| EP3389680C0 (en) | TREATMENT OF INTRAHEPATIC CHOLOSTASISIS AND ASSOCIATED LIVER DISEASES | |
| IL320533A (en) | Methods and compositions for treating disorders and diseases involving RDH12 | |
| IL262713A (en) | Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases | |
| PH12017500239A1 (en) | Abiraterone acetate formulation and methods of use | |
| MX2017001103A (es) | Derivados de indolizina que son aplicables a enfermedades neurodegenerativas. | |
| ZA201807438B (en) | Methods of treating ocular conditions | |
| ZA201703467B (en) | Methods of treating ocular conditions | |
| MA40406A (fr) | Procédés et compositions de diagnostic et de traitement des maladies inflammatoires chroniques de l'intestin | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| PL3236983T3 (pl) | Nowy peptydowy inhibitor PI3K gamma do leczenia chorób układu oddechowego | |
| IL280952A (en) | Methods and drug compounds for the treatment of ophthalmic diseases | |
| IL272604A (en) | Preparations for the treatment of intestinal infections | |
| IL247369A0 (en) | Compounds and methods for the treatment of bone diseases | |
| EP3402531A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | |
| IT201800011030A1 (it) | Metodo per la determinazione quali-quantitativa del microbiota intestinale | |
| HK1236807A1 (en) | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same | |
| HK40008876A (en) | Methods and compositions for treatment of disorders and diseases involving rdh12 | |
| HK40008112A (en) | Compositions and methods for treatment of cardiac diseases |